Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells
    3.
    发明申请
    Prediction of response to docetaxel therapy based on the presence of TMPRSSG2:ERG fusion in circulating tumor cells 审中-公开
    基于TMPRSSG2:ERG融合在循环肿瘤细胞中的存在对多西紫杉醇治疗的预测

    公开(公告)号:US20110166030A1

    公开(公告)日:2011-07-07

    申请号:US12924506

    申请日:2010-09-28

    IPC分类号: C40B30/00

    CPC分类号: G01N33/57434 G01N2800/52

    摘要: A method for predicting with high specificity from RTPCR detected markers if a patent is likely to respond to docetaxel treatment is disclosed. RTPCR detects the presence of absence of certain mutations due to fusion events. Together, with other protein markers, additional stratification is possible to identify patents suited for docetaxel therapy as opposed to for alternative treatments.

    摘要翻译: 公开了一种如果专利可能对多西紫杉醇治疗作出反应,则从RTPCR检测的标记物以高特异性预测的方法。 RTPCR检测由于融合事件而不存在某些突变。 与其他蛋白质标记一起,额外的分层可以鉴定适合多西他赛治疗的专利,而不是替代治疗。